Peer Schatz, Chief Executive Officer First Quarter 2012Sample & Assay Technologies. 3. Agenda. QIAGEN review. 2011 results. 2012 outlook. Appendix

Sample & Assay Technologies

1

Investor presentationPeer Schatz, Chief Executive OfficerFirst Quarter 2012

1


22

Forward looking statements

Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's

products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between business segments, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's

products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's

products to integrated solutions and producing such products; the ability of

QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's

new products and the integration of acquired technologies and businesses. For further

information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Regulation G: Some of the slides in this presentation contain certain summary information about QIAGEN N.V.’s

sales, gross profit, operating income, net income, and earnings per share, which information is presented on a “non-GAAP financial measures”

basis rather than in accordance with U.S. generally accepted accounting principles (GAAP). Please review QIAGEN’s

press releases, which can be found in the Investor Relations section of QIAGEN’s

webpage under www.QIAGEN.com, for information on the Company’s operating income, net income, and earnings per share presented

on a GAAP basis. Such GAAP-basis information will also be contained in the Company’s reports on Form 20-F or Form 6-K to be filed with or furnished to the U.S. Securities and Exchange Commission.

2


3

Agenda

QIAGEN review

2011 results

2012 outlook

Appendix

3


44

Pharma

Making improvements in life possible

4

Molecular revolution is only just beginning

How do we secure food supplies and protect

public safety?

Applied Testing AcademiaMolecular Diagnostics

How do we fight diseases

and improve healthcare?

How do we develop

better and safer drugs?

How do we achieve

scientific breakthroughs

even faster?


55

World leader in Sample & Assay Technologies

Enable access to molecular information

Biological sample to digital result

> 500 core products

Consumable kits and instruments

> 500,000 customers worldwide

Molecular Diagnostics

Applied Testing

Pharma

Academia

Innovative power

~2,500 patents

Healthy financial position

Strong cash conversion

Improving margins

2011 key figures (In $ millions)

Net sales 1,169.7 + 4% (CER)

Adjusted net income 234.4 +5%

Adjusted EPS

(In $ per share) 0.98

Employees ~3,900

5

CER –

Constant exchange rates


66

Broad product offering with common purpose

From biological sample to clinical result

6

SAMPLE Technologies ASSAY

TechnologiesBIOLOGICAL SAMPLE

VALUABLE MOLECULAR

INFORMATION


7

Instruments

Products for use with kits

Automating entire workflows

Many detection technologies

Real-time PCR

Pyrosequencing

Isothermal amplification

Hybrid capture

Consumables

> 500 core product groups

Specialized kits with all materials

> 90% of products sold to more than one customer class

Comprehensive product range to support workflows

2011 net sales: $1,169.7 million

7

~85%~15%


88

Operating in attractive markets

8

Applied Testing AcademiaMolecular Diagnostics

2011 sales

($1,169.7 m)

~47%

(Other MDx: ~32%)(U.S. HPV: ~15%)

~7% ~20% ~26%

Long-term growth opportunities +++ +++ ++ +Key customers

Reference labs

Hospitals

Forensic labs

Industrial

Government agencies

Big Pharma

Specialty / Biotech

CROs

Government research

Academic and private labs

Highlights

Personalized Healthcare

Virology

QuantiFERON

HPV

Forensics

Vet and food safety portfolio

GeneGlobe:

Pathway analysis

Biomarkers

Trusted brand

Involvement with breakthroughs

Translational research


9


Supporting important treatment decisions

World leader in molecular technologies for human healthcare

Prevention

Profiling

Personalized Health

Point of Need

Top products

QIAsymphony

RGQ

Viral load assays (HIV/HCV/HBV, etc.)

Companion diagnostics

(KRAS/EGFR, etc.)

digene HPV test QuantiFERON®

TB test Esoteric virus panel tests DNA / RNA sample kits PCR assay technologies

Business characteristics

Fastest-growing area of

in vitro diagnostics

Advanced technologies Very low penetration Fragmented market Strict regulations

QIAGEN

advantages

HPV leadership

Broad range of assay tests

(outside U.S.)

Extensive pipeline to build

U.S. testing menu

Automation systems

> 15 companion diagnostic

co-development projects


10

Applied Testing

Industrial use of molecular technologies

Rapid growth in fast growing commercial areas:

Human ID / forensics

Veterinary testing

Food safety

Top products

Global leader in human ID

sample kits

Broad range of human ID

assays (outside U.S.)

> 70 food safety assay tests

Veterinary assays for

commercial livestock


Dynamic growth –

but from small base

Established molecular standards in human ID

Internationalization

Growing demand for veterinary and food safety

Premium to immunoassays

QIAGEN advantages

Industry leader in human ID / forensics

Global presence

Building portfolio in

veterinary and food safety

Mobile testing device

opportunities


11

Pharma

Partner in gene-based

R&D initiatives

Helping set new standards in drug discovery and development

Top products

Sample technologies:

DNA / RNA prep kits Assay technologies:

SABioscience

products

siRNA

/ miRNA

kits Quality manufacturing


Shift to gene-based R&D Research: Soft results Development: Solid growth

Biotech expansion and

greater use of CROs

Increasing links to academia

QIAGEN advantages

SABioscience

gene

expression assays

Products covering entire R&D continuum

Support basic discovery to

companion diagnostics

Ability to address demands

of global operations


12

Academia

Advancing the understanding of molecular life

Enabling cutting-edge life sciences research and breakthroughs around the world

Top products

Sample technologies:

DNA / RNA prep kits Assay technologies:

SABioscience

disease and pathway analysis

miRNA

/ siRNA

kits

DNA methylation

and

epigenetics


~ 45,000 public and

private research labs

Largely dependent upon

government funding

Essential innovation driver

for molecular diagnostics

QIAGEN advantages

Origins of QIAGEN High-quality reputation

Proven contributor to major

scientific breakthroughs

Quickly commercializing

new opportunities


1313

Preparing for a new growth phase after disruptions

2007 2009 2011 2013

Expand life sciences leadership and build up MDx Targeted acquisitions Customer relations Global expansion

Growth drivers for next wave

QIAsymphony

Expanding test menu

High-growth markets

Personalized Healthcare

Updatedgrowth plan

Recession impact

HPV uptake in U.S.

R&D funding

13

Project Full Potential:

1. Accelerate sales growth

2. Reallocate resources


1414

Strategic initiatives to drive growth and innovation

Drive platform success

Roll out QIAsymphony

worldwide

Advance QIAensemble

strategy

Leverage leadership in Sample & Assay Technologies

14

Add content

New tests across all customer classes

Broaden geographic presence

Target high-growth emerging markets

Grow efficiently and effectively

Sustained growth and improved profitability

Leverage synergies across customer classes

Best-in-class team and work environment


Applied Testing

Academia


15

2011 achievements drive 2012 goals

Strategic initiatives 2011 achievements 2012 goals

>550 QIAsymphony

systems

Launch QIAensemble

Decapper

Update QIAensemble

strategy

>750 QIAsymphony

systems

Improve HPV automation

Selected submissions:

KRAS (Erbitux)

KRAS (Vectibix)

Influenza

careHPV

QuantiFERON-TB test

Novel blood cancer assays

Selected submissions:

EGFR (Tomtovok)

artus

CMV

QuantiFERON

CMVBRAFartus

CT/GC

Target high-growth regions: Eastern Europe, Asia, Americas

Grow at a faster pace than 2011

Drive productivity initiatives

Improve margins


Add content

Grow efficiently and effectively

Broaden geographicpresence

15

Dynamic growth in top 7 EGM

Direct entry in India and Taiwan

Drive sales and earnings growth

Launch productivity initiatives

Reallocate resources


16

Driving global QIAsymphony

expansion

Most versatile molecular testing system

Achieved 2011 goal

>550 systems installed

Across all customer classes

60% Molecular Diagnostics

40% Applied Testing, Pharma, Academia

Increasing consumable use

Ambitious 2012 goal

Target: >750 placed systems by end 2012

Significantly expanded lead pipeline

Extending capabilities

Launching software update

FFPE sample processing

Key features for Applied Testing

Reduction in hands-on time

Adding new content


Certal bioprocessing

Human ID and food safety

QIAsymphony

placements

Installed base

End 2011

> 550

2008

500

1,500

(QIAsymphony

SP launch)

2012 target

1,000> 750

Ongoing global expansion

16

FFPE –

Formalin-Fixed, Paraffin-Embedded


1717

QIAsymphony: Across all customer classes

Americas~40%

Europe~30%

Asia-Pacific/Japan~30%

Asia-Pacific/

Japan~10%

Europe~55%

Americas~35%

Applied Testing

Pharma

Academia~40%


~60%

>550 QIAsymphony

placements by end 2011


18

QIAsymphony

RGQ: Meeting broad needs

Molecular Diagnostics Applied Testing Pharma Academia

Viral load monitoring

Gene expression analysis

Genetic testing

Pathogen identification

Protein expression screening

Genotyping

Infectious disease testing

Veterinary diagnostics

Forensic testingApplied research


Quality manufacturing

18


1919

QIAsymphony

RGQ: Driving “lean labs”

Typical mid-sized European hospital laboratory

49 molecular tests

Annual volume: ~70,000 tests and growing

Process tests for 8 hospitals and clinics

Issues

Redundant instruments

Administrative tasks

Need for consolidation

Conducted “lean”

analysis

Minimize waste

Consolidate platforms and vendors

Outcome: 38 of 49 tests

now on QIAsymphony

RGQ

Case study: St. Elisabeth Hospital, Tilburg, The Netherlands

19

Assay providers

Com

petit

ors

Com

petit

ors

Past Present

Past Present

Platform providers


20

QIAsymphony

RGQ overview

QIAsymphony

SP QIAsymphony

AS Rotor-Gene Q (RGQ)


21

QIAsymphony

SP/AS system overview

USB portsFor bi-directional data exchange

UV lampDecontaminate the workable and minimize sample cross-

contamination

Assay drawerProvides active cooling PCR assays.

Eluate

drawerProvides a choice of elution including cooling

Waste drawerStores solid and liquid waste separately

Reagent and consumables drawerSupports consumables and 2 reagent cartridges

Sample drawerAccommodates a wide range of

sample input formats

Touch screenFor intuitive operation of

complete system

Network connection

Robotic arm4-channel with tip guards

UV lampDecontaminate the workable and minimize sample cross-

contamination

Separation window and eluate

transfer channelEnables direct transfer of eluates

from the SP to the AS moduleRobotic arm4-channel with tip guards

Reagent and eluates

drawerSupports master mix ,reagents and preracked

consumables

21


22

Other QIAGEN systems

Ongoing menu expansion

22


Applied Testing

Pharma

Adding content across customer classes and instruments

Biomarkers Pre-molecular disease testing

BioprocessingForensics /

Food safety

Pathway analysis

QIAsymphony

RGQ

Academia

therascreenartus Ipsogen

Investigatormericon

Certaltherascreenartus Ipsogen

therascreenartus Ipsogen

QuantiFERON-TB QuantiFERON-CMV

GeneGlobe

GeneGlobeQuantiFERON-TB QuantiFERON-CMV


2323

Adding content to automation platforms

Selected key menu submissions

23

QIAsymphony(Marketed)

QIAensemble(In development)

2011submissions

Planned submissions2012

Planned submissions≥

2013

careHPV

artus Influenza

QuantiFERON

tests

therascreen KRAS (Vectibix)

therascreen KRAS (Erbitux)

QuantiFERON

CMV

artus CT/NG

artus CMV

artus HIV

artus HCV

therascreen JAK2

therascreen EGFR

therascreen KRAS (lung)

therascreen BRAF

therascreen BCR-ABL

artus CT/NG

Rotor-Gene Q(Marketed)


24

Two KRAS FDA submissions in H1 2011

> 15 co-development projects

Full platform range

QIAsymphony

RGQ

Rotor-Gene

Pyrosequencing

Strong IP EGFR JAK2 PI3K

Meeting FDA standards

Support global trials and commercialization

Content

IndependenceGlobal

presence

Instruments

Manufacturing

Regulatory

Leadership in Personalized Healthcare


2525

Rapid growth in Personalized Healthcare

25

Personalized Healthcare sales2011 estimate: ~$75 million

Co-developmentprojects(Molecular Diagnostics)

Other(Academia / Pharma)

Commercial

biomarker assays

(Molecular

Diagnostics)

Milestone payments

Broad portfolio for solid and hematological

tumors


Biomarker analysis and validation

Automation instruments

Third-party manufacturing (OEM)

Ongoing strong double-digit sales expansion

NEW EGFR biomarker test approved in Japan

(December 2011)

NEW ALK biomarker

(January 2012)

NEW IGH1 / IGH2 biomarkers

(January 2012)


26

Leading co-development project portfolio

Selected Personalized Healthcare co-development projects

Project Partner Indication Biomarker Status

Eribitux

(cetuximab)

Colorectal

cancer KRAS Submitted U.S.

(PMA) in H2 2011

Vectibix

(panitumumab)

Colorectal

cancer KRAS Submitted U.S.

(PMA) in H2 2011

PF-00299804

(dacomitinib)

Lung cancer

(NSCLC) KRAS In development

Iressa

(gefitnib)

Lung cancer

(NSCLC) EGFR CE-IVD kit in Europe and

other non-U.S. markets

Tomtovok

(afatinib)

Lung cancer

(NSCLC) EGFR U.S. submission planned

for 2012

Early-stage compound Blood cancer JAK2 In development

Not disclosed Confidential partners Oncology and non-oncology Various In development

Partner of choice: Industry-leading 15 projects under way

26


27

1 Rank order estimates for scientific and commercial potential of development of companion diagnostics in various therapeutic areas, based on both qualitative factors (e.g., expert interviews) and quantitative factors (e.g., data on price premiums for drugs launched in the same therapeutic class). Results should be taken as directional only.

Source: McKinsey Quarterly February 2010

2.8

2.6

2.4

2.22.0

1.8

1.61.4

1.2

1.0

0.8

0.60.4

0 1.4 1.5 1.6 1.7 1.8 1.9 2.5 2.6 2.7Economic potential of companion diagnostics1

Scientific potential of companion diagnostics1

Growth factorsAntihistamines

Diabetes

Asthma

Autoimmune drugs

OncologyAnti-infectives

Anticoagulants

AntipsychoticsCNS drugs

Antidepressants

Statins

Proton pump

inhibitors

Antihypertensives

Anti-inflammatories

Antiarrhythmics

Companion diagnostics going beyond oncology


2828

TB remains a major health issue

QuantiFERON-TB: New gold standard for latent TB detection

Superior to 120-year-old Tuberculin Skin Test (TST)

No impact from BCG vaccination

Only one visit

U.S:, Europe and Japan approval and reimbursement

R&D collaboration with Max Planck Institute (Berlin)

Follow-up PCR-based test

Assess risk for latent TB activation

QuantiFERON-TB: New gold standard

Test group QuantiFERON-TB Gold Tuberculosis Skin Test (TST)

Specificity1 99.2% 65.9%

Sensitivity for active TB 89.0% 76.0%

Bacille

Calmette-Guerin (BCG) vaccination

Unaffected2 20% -

40% are false positive3

Non-TB mycobacterial

infections (NTM)

Mostly unaffected4 In U.S.-born, up to 50% false positive5

28

1

Menzies

D, et al., 2007 2

Mori t., et al., 2004 3

Farhat

M., et al., 2006 4

Anderson P., et al., 2000 5

von Reyn

C.F., et al., 2001

Ongoing strong double-digit sales expansion

“TB is an old disease that never went away, and now it is evolving with a vengeance.”-

Zsuzsanna

JakabWHO regional director Europe (Reuters, Sept 2011)


29

Total market: > $710 million

1)

World Health Organization (Diagnostics for Tuberculosis, 2006)

41

16

Total tests: > 57 million

$340 $370

QuantiFERON-TB: Untapped market potential

Guidelines completed in most countries

U.S. CDC guidelines on latent TB testing

Updated guidelines in other countries

Broad support in clinical publications

QFT expected to be adopted in UK as first-line screening for immigration

Current markets

Healthcare workers / employee screening

Immigration / travel

College / education

Military Future markets


Broad applications TB testing market in developed world1

Latent TB detection critical to reducing active disease burden


30

QuantiFERON-TB Gold target markets

Screening

Immigrants/refugees

Expatriate protection

Community living

Travel medicine

Professions at risk

Government employees

International assistance (NGO, etc.)Technical employees (Oilfield workers,

international service companies, etc.)Managers and family membersRetirement homes, etc.Nursing homesPrisons

Healthcare workers

Transport workers

Public service

AirlinesRailwaysUrban transport companies

PoliceAmbulance crewsFirefightersMilitary

Diplomatic corps

Protection of the

immunosuppressed

Screening

pre-immunosuppressive

treatment

Immune suppressive

conditions

Immune monitoring disciplines

TNFa

blockers

Transplantation

Crohn’s

disease DermatologyRheumatology

DialysisCancerHIV / AIDSHematologyOncology

Clinical patients

Contact tracing

Non-pulmonary TB

Children

Patients with general

symptoms

Public health

Hospitals

QuantiFERON-TB Gold application areas

30

Global addressable market: > 50 million tests


31

Expanding geographic presence

Full-year 2011 net sales by region

Targeting expansion in Eastern Europe and Latin America

48%

34%

17%Asia-Pacific / Japan+8% CER

Europe / Middle East / Africa+7% CER

Americas+2% CER

Brazil

Russia

Future opportunityIndia

2011 direct entryChina

South Korea

Turkey

Mexico

Top 7 emerging markets:12% of net sales / +21% CER

CER –

Constant exchange ratesEMEA –

Europe / Middle East / Africa

31


32

Addressing HPV market dynamics

32

2011

U.S. –

Solidify market leadership

Driving HPV testing conversion

Moving toward ~50% penetration

Guidelines favor HPV / Pap co-screening

Untapped opportunities

Working with customers

Renewing major multi-year contracts

Benefits: Gold standard and switching risks

Providing automation improvements

QIAensemble

Decapper

launched in Q4 2011

Building on HPV status

Blockbuster assay

Strong relations with many labs

Rest of world –

Convert to primary screening

Unrivaled clinical data

Regional actions

Europe: Leader

Latin America: Mexico implementation

Asia-Pacific/Japan: Opportunities

MolecularDiagnostics(non-HPV)

~27%

Pharma~20%

Academia~26%

Applied Testing~7%

$1,167.9 million

MolecularDiagnostics

(HPV)

U.S. ~15%

Ex-U.S. ~5%

All figures at actual exchange rates

QIAGEN sales overview

32

~47%

32


33

HPV leader with clinical data and automation

Comparative performance of selected HPV tests

digene®

HPV testcobas®

HPV testAPTIMA®

HPV test

Co-testing for women ≥30

Sensitivity for CIN 3+ 100.0%1,2 90.0%8 90.9%10

NPV for CIN 3+ 100.0%3 99.7%8 99.8%10

Sensitivity for CIN 2+ 98.0%4 83.2%8 75.0%10

NPV for CIN 2+ 100.0%3 99.1%8 99.0%10

NILM positivity rate 3.99%5 6.7%8 5.0%10

Reflex testing for ASC-US


NPV for CIN 3+ 99.5%6 99.7%8 99.3%10


NPV for CIN 2+ 98.9%6 99.2%8 97.8%10

1. Mayrand

MH et al. N Engl J Med. 2007;357:1579-1588; 2. Clavel

C et al. Br J Cancer. 2001;84:1616-1623; 3. Lorincz

A, Richart

R. Arch Pathol Lab Med. 2003;127:959-968; 4. Salmeron

J et al. Cancer Causes Control. 2003;14:505-512; 5. Castle PE et al. Obstet Gynecol. 2009;113:595-600; 6. Solomon D et al. J Natl Cancer Inst. 2001;93:293-299. 7. Cervista®

HPV HR Package Insert 2009. 8. cobas®

HPV Test Package Insert 2011. 9. ACOG Committee on Practice Bulletins–Gynecology. Obstet Gynecol. 2009;114:1409-1420 10. APTIMA HPV Assay Package Insert 2011 502170 REV A

Gold standard HPV test

>80 m tests shipped

>1 m women in clinical trials

Unrivaled data

Improving automation

Decapper

launch end-2011

Other projects progressing

Driving U.S. market conversion

Moving toward 50% penetration

Renewing multi-year contracts

Worldwide opportunities

Mexico HPV screening

European leader

Asia-Pacific / Japan expansion

33


34


~47%(Other MDx: ~32%)(U.S. HPV: ~15%)

+7% CER

Focusing on multiple growth drivers

Applied Testing~7%

+1% CER

Pharma~20%

+4% CER

Academia~26%

+2% CER

Personalized Healthcare: Global expansion

Profiling: QIAsymphony

rollout

QuantiFERON-TB: Building momentum

Ongoing growth in human ID, food safety

Improving instrument sales

Demand for molecular pathway toolsR&D shift to AsiaIndustry consolidation

Translational medicine

Expansion into high-growth markets

Uncertain spending in U.S. and Europe

HPV: Leverage U.S. leadership, expand globally

2011 sales 2012 sales outlook2012 perspectives

34


3535

Sustainable sales expansion

2012: Improving CER growth vs. 2011

2013 onwards: Return to faster growth

Margin improvement

New projects to unlock efficiency gains

End-2013 target: ≥

31% adjusted operating margin

Taxes and capital allocation

Further tax rate reductions

Capital allocation measures under review

Delivering shareholder returns

35

1

2

3

CER –


Focus on maximizing bottom-line growth and delivering shareholder returns

Drive adjusted EPS

growth


36

Gross margin+Site

consolidation- Product mix

+ Pricing strategy

+ Procurement

Levers to improve adjusted operating margin

Adjusted operating income margin overview

2011actual

27%

(Q4: 29%)

2013

target

>29%(Q4: >31%)

Gross margin

R&D

2012

target

~27-28%(Q4: ~30%)

SG&A+ Sales models

+ Shared services

+ Procurement

+Streamlined portfolio

- Clinical trials

+ Procurement

- Product mixInstruments

(QIAsymphony) HPV

- CDx

deals

-

Post-acquisition investments

+ Pricing strategy

36

SG&A+ Sales models

+ Shared services

+ Procurement

R&D

+Portfolio focus

+ Procurement


37

Solid balance sheet

As of December 31 2011 2010

Group liquidity (In $ millions) 275.7 934.5

Net debt (-) / net liquidity (+) (In $ millions) -314.2 +61.5

Shareholder equity ratio 68% 63%

Net debt / adjusted EBITDA ratio 0.9 -0.1

Healthy financial position and strategic flexibility, new credit

facility

Leverage ratio: Net debt / EBITDA

For further information on adjustments, please refer to the reconciliation tables in QIAGEN's

Q4 2011 earnings release or appendices

0.00.2

3.3

2.2

0.4

- 0.1

0.9

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

2005 2006 2007 2008 2009 2010 2011

Digene

acquisition

Cellestis

and Ipsogen

acquisitions

Fourth quarter / Full-year 2011 results 37


38

Efficiency project overview

Taking actions to drive growth and innovation

Free up resources and reallocate to strategic initiatives

38

Excellence initiatives

Sales channel initiatives

New pricing framework

Supply chain efficiency

Site review and consolidation

Improved processes

Portfolio focus on growth areas

Procurement

savings

Shared

services

Streamline and delayer

Reduce duplications

Project launched in late 2011

Increase

efficiency

and effectiveness

Areas

of focus

Streamline and delayer organization

(~8 -

10% workforce reduction)

Focus R&D on growth areas

Optimize capacity utilization

Expand shared services

2012 pre-tax savings goal: $50 million

Reallocate to strategic initiatives

$75 m charge in Q4 2011 (Of which $30 m cash)

Additional charge planned for 2012

Commercial

Operations

R&D

Support Services

Organization


39

QIAGEN group debt instruments

Improved financing structure

New revolving credit facility (RCF)

€

400 million signed in December 2011

Very attractive pricing (Initial margin: EURIBOR + 80 bps)2

International bank consortium

5-year maturity

Cancelled old $150 million RCF

Benefits

Extended maturity profile

Increased flexibility

Improved balance sheet efficiency

Repaid term loan

$350 million loan balance due in July 2012

Sources:

Cash on hand

€110 million from new RCFConvertible bond

$145 m

Convertible bond$300 m

Old RCF$150 m

(All undrawn)

Term loan$425 m



New RCF

$520 m1

(Of which $380 m undrawn)

As of December 31, 2010 As of December 31, 2011

(1)

€400 million revolving credit facility at EUR-USD exchange rate of €1.00 = $1.30(2)

Subject to a leverage-based margin rachet

and other market-standard pricing components / EURIBOR -

Euro InterBank

Offered Rate

39


4040

Track record of growth and innovation

Robust development pipeline

Strong free cash flow

World leader in Sample & Assay Technologies

Driving the dissemination of molecular testing

Key considerations: Strong growth potential

40

Attractive and growing markets

Building leadership in Molecular Diagnostics

Highly competitive offering in Academia, Pharma

and Applied Testing

Capitalizing on diverse growth opportunities

Pioneer in Personalized Healthcare

Expansion into high-growth markets


41

Agenda

QIAGEN review

2011 results

2012 outlook

Appendix

41


42

H2 2011: Strong performance

+9% CER sales growth

2011: Progress on strategic initiatives


Add content

Expand geographic presence

Improve efficiency and effectiveness

2012: Accelerating growth and innovation

Deliver faster sales and earnings growth

Strong finish in 2011 builds momentum for 2012

Full-year 2011 key figures (In $ millions)

Net sales 1,170 + 4% CER


Adjusted EPS


CER –


Q4 2011 key figures (In $ millions)

Net sales 334.4 + 17% CER


Adjusted EPS




43

FY 2011: H1 vs. H2 key results

H1 2011 and H2 2011 total net sales

(Change vs. 2010 periods)

H1 2011 and H2 2011 adjusted net income(Change vs. 2010 periods)

-1% CER

+3%

+7%

Strong H2 2011 results form basis to accelerate growth in 2012

+9% CER1


(1)

H2 2011 total net sales include approximately four percentage points of organic growth and approximately five percentage points from the acquisitions of Cellestis

(as of August 29) and Ipsogen

(as of July 12)

H1 2011 H2 2011H1 2011 H2 2011


44

In $ millions

(unless indicated) Q4 2011 Q4 20101 Change

Net sales 334.4 286.0 17%

Net sales (CER) 335.7 286.0 17%

Gross profit 201.7 189.0 7%

Adjusted gross profit 229.3 205.5 12%

Operating income -19.6 50.8 -139%

Adjusted operating income 95.6 82.4 16%

Net income -0.4 36.3 -101%

Adjusted net income 73.6 62.0 19%

EPS (In $ per share) 0.00 0.15

Adjusted EPS (In $ per share) 0.31 0.26

Weighted average number of diluted common shares (In millions) 236.7 239.4

Q4 2011

Summary income statement

CER –

Constant exchange rates(1) Net income and EPS include in 2010 a one-time tax benefit of $3.0 million related to the restructuring of

acquired foreign subsidiariesFor further information on adjustments, please refer to the reconciliation tables in QIAGEN's

Q4 2011 earnings release or appendicesNet income and adjusted EPS based on net income attributable to shareholders of QIAGEN N.V.

44


45

Q4 2011

Reconciliation of reported to adjusted figures

In $ millions (except EPS)

Net sales

Gross profit

Operating income

Pretax income

Income

tax

Net income

Diluted EPS(1)

Reported results 334.4 201.7 -19.6 -22.1 21.3 -0.4 0.00

Adjustments:

Business integration, acquisition related and restructuring costs

8.4 83.0 83.0 -29.2 53.8 0.23

Purchased intangibles amortization 18.8 26.4 26.4 -9.2 17.2 0.07

Share-based compensation 0.4 5.2 5.2 -1.2 4.0 0.02

Other non-recurring income and expense 0.6 1.2 -2.2 -1.0 -0.01

Total adjustments 27.6 115.2 115.8 -41.8 74.0 0.31

Adjusted results 334.4 229.3 95.6 93.7 -20.5 73.6 0.31

(1) In $ using 236.7 million diluted shares Table may have rounding differencesNet income and adjusted EPS based on net income attributable to shareholders of QIAGEN N.V.

45


46

Q4 2011

Currency impact

In $ millions ActualConstant

exchange rates (CER)

Change due to currency

Net sales in USD 121.1 121.1 0.0

Net sales in EUR 85.3 85.9 -0.6

Net sales in GBP 22.4 22.5 -0.1

Net sales in JPY 17.8 16.6 1.2

Net sales in other currencies 87.8 89.6 -1.8

Total 334.4 335.7 -1.3

CER –

Constant exchange ratesOther currencies include CAD, TRY, SEK, CHF, AUD, BRL, CNY, MYR,

SGD, KRW, HKD, MXN, INR, TWD

46


47

FY 2011

Summary income statement

In $ millions (unless indicated) FY 2011 FY 20101 Change

Net sales 1,169.7 1,087.4 8%

Net sales (CER) 1,135.8 1,087.4 4%

Gross profit 749.8 715.6 5%

Adjusted gross profit 832.5 779.6 7%

Operating income 99.6 188.5 -47%

Adjusted operating income 319.6 308.2 4%

Net income 96.0 144.3 -33%

Adjusted net income 234.4 222.7 5%

EPS (In $ per share) 0.40 0.60

Adjusted EPS (In $ per share) 0.98 0.93

Weighted average number of diluted common shares (In millions) 239.1 240.5

CER –

Constant exchange rates(1) Net income and EPS include in 2010 a one-time tax benefit of $12.0 million related to the restructuring of acquired foreign subsidiariesFor further information on adjustments, please refer to the reconciliation tables in QIAGEN's

Q4 2011 earnings release or appendicesAdjusted net income and adjusted EPS based on net income attributable to shareholders of QIAGEN N.V.

47


48

FY 2011

Reconciliation of reported to adjusted figures

In $ millions (except EPS)

Net sales

Gross profit

Operating income

Pretax income

Income

tax

Net income

Diluted EPS(1)

Reported results 1,169.7 749.8 99.6 96.2 -1.3 96.0 0.40

Adjustments:

Business integration, acquisition related and restructuring costs

9.6 101.5 101.5 -34.8 66.7 0.28

Purchased intangibles amortization 70.2 96.9 96.9 -32.9 64.0 0.27

Share-based compensation 1.7 19.5 19.5 -4.2 15.3 0.06

Other non-recurring income and expense 1.2 2.1 -8.5 0.9 -7.6 -0.03

Total adjustments 82.7 220.0 209.4 -71.0 138.4 0.58

Adjusted results 1,169.7 832.5 319.6 305.6 -72.3 234.4 0.98

(1) In $ using 239.1 million diluted sharesTable may have rounding differencesAdjusted net income and adjusted EPS based on net income attributable to shareholders of QIAGEN N.V.

48


49

Agenda

QIAGEN review

2011 results

2012 outlook

Appendix

49


50

FY 2012 outlook and assumptions

Adjustments to operating income FY 2012

Equity-based compensation (In $ millions) ~21 -

22

Amortization of acquired intellectual property (In $ millions) ~110

Business integration, acquisition, and restructuring (In $ millions) ~30

Adjusted tax rate ~21 -

23%

Weighted average number of fully diluted shares outstanding (Based on $15.00 share price)2 ~239 million

CER –

Constant exchange rates(1)

Total sales is comprised of organic growth as well as the Cellestis

and Ipsogen

acquisitions These expectations do not take into account any acquisitions that could be completed during 2012

(2) Every

$1.00 increase of share price results in ~1 million increase of weighted average number of fully diluted shares outstandingFor further information on adjustments, please refer to the reconciliation tables in QIAGEN's


50

Outlook FY 2012

Total net sales1 +6-8% CER

Adjusted diluted EPS $1.03 -

1.05

Adjusted results are provided to give addition insight into QIAGEN's

financial performance. These are non-GAAP financial measures that QIAGEN believes should be considered in addition to the reported results prepared in accordance with U.S. GAAP, but should not be considered as a substitute. Adjusted diluted EPS excludes equity-based compensation; amortization of acquired intellectual property; business integration, acquisition and restructuring charges; and their respective revisions to the tax rate.


51

Q1 2012 outlook and assumptions

Adjustments to operating income Q1 2012

Equity-based compensation (In $ millions) ~5

Amortization of acquired intellectual property (In $ millions) ~28

Business integration, acquisition, and restructuring (In $ millions) ~7

Adjusted tax rate ~26%

Weighted average number of fully diluted shares outstanding (Based on $15.00 share price)2 ~239 million

CER –

Constant exchange rates(1)

Total sales is comprised of organic growth as well as the Cellestis

and Ipsogen

acquisitions These expectations do not take into account any acquisitions that could be completed during 2012

(2) Every

$1.00 increase of share price results in ~1 million increase of weighted average number of fully diluted shares outstandingFor further information on adjustments, please refer to the reconciliation tables in QIAGEN's


51

Outlook Q1 2012

Total net sales1 +8-9% CER

Adjusted diluted EPS ~$0.20

Adjusted results are provided to give addition insight into QIAGEN's

financial performance. These are non-GAAP financial measures that QIAGEN believes should be considered in addition to the reported results prepared in accordance with U.S. GAAP, but should not be considered as a substitute. Adjusted diluted EPS excludes equity-based compensation; amortization of acquired intellectual property; business integration, acquisition and restructuring charges; and their respective revisions to the tax rate.


52

QIAGEN trends

2009 2010 2011 2012 estimate

R&D expense (In $ millions) 108 126 131 ~145

Capital expenditures (% of net sales) 7% 9% 7% ~7%

Depreciation (% of net sales) 4% 4% 5% ~5%

Amortization (% of net sales) 8% 9% 9% ~10%

52


53

Agenda

QIAGEN review

2011 results

2012 outlook

Appendix

53


54

QIAsymphony

SP system overview

Sample

1

2

3

4

5

6

7

8

9Sample input

Reagent cartridges

Filter tips

Plastics

Waste compartment

Elution slot 1 (cooled)

Elution slots 2–

4

Lysis

station (heated)

Purification station

1 2

3

4 5

10

7

8 9

6

10 Robotic arm

Input

Lysis Purification

Elution

Reagents and consumables Waste Elution

Transfer

54

http://commons.wikimedia.org/wiki/Image:DIN_4844-2_Warnung_vor_heisser_Oberflaeche_D-W026.svg

http://commons.wikimedia.org/wiki/Image:DIN_4844-2_Warnung_vor_Kaelte_D-W017.svg


55

QIAsymphony

AS system overview

1

2

4

5

6

1

2

3

384 disposable tips Different sizes

Auto recognition

3x PCR output adapters Rotor-Gene RGQ

96 well formats

Capillary formats

Three outputs per run

fully cooled

3x input adapters

Loading reagents

and samples

Active cooling

Reagents / Eluates

drawer Assay drawer

Transfer position

Tip waste

55


56

Employees as of December 31, 2011

Americas Europe AsiaRest of World

Total Q4 2011

Total

Q4 2010 Change

Production 238 583 99 4 924 841 10%

R&D 153 556 36 13 758 740 2%

Sales 511 555 409 34 1,509 1,302 16%

Marketing 55 179 40 7 281 251 12%

Admin 115 270 69 12 466 453 3%

Total 1,072 2,143 653 70 3,938 3,587 10%

56


57

HIV

Human Immunodeficiency

Virus HKD

Hong

Kong

DollarHPV Human Papilloma

VirusID

IdentityIfp

Institute for

Product

QualityINR

Indian RupeeIP

Intellectual

PropertyJPY

Japan YenKRAS

Kirsten rat Sarcoma

Viral

Oncogene

Homolog KRW

South Korean

WonLDT

Laboratory Developed

TestsM MillionMDx

Molecular

DiagnosticsMXN

Mexican

PesoMYR

Malaysian

RinggitNIH

National Institutes of HealthPCR

Polymerase

chain

reactionR&D

Research & DevelopmentRoW

Rest of WorldRGQ

Rotor-Gene QRNA

Ribonucleic

AcidSEK

Swedish

KronaSGD

Singapore

DollarTB

Tubercles

BacillusTRY Turkish New

LiraUS

United States

Adj

AdjustedAUD

Australian DollarBRAF

Serine/Threonine-Protein Kinase

B-RafBRL

Brazilian RealCAD

Canadian Dollar CDx

Companion diagnosticsCE European Conformance MarkCER Constant Exchange RatesCHF

Swiss Franc CMV

Cytomegalovirus CNY

China Yuan RenminbiCT/NG

Chlamydia Trachomatis/ Neisseria

GonorrhoeaeDNA

Deoxyribonucleic acidE EstimatedEBV

Epstein-Barr virus EGFR

Epidermal Growth Factor Receptor EPS Earnings per ShareEU

European UnionEUR

EuroExcl.

ExcludingFDA

Food and Drug AdministrationFX Foreign Exchange GAAP

Generally Accepted Accounting PrinciplesGBP

British PoundHBV

Hepatitis B Virus HCV

Hepatitis C virus

List of abbreviations

57


58

Your contacts

E-mail: [email protected]

Angela SchmidtAssistant

Investor RelationsTel: +49 2103 29 11709Mobile: +49 1520 18 11709E-mail: [email protected]

2012 calendarQ1 results Media release: April 25 (22:00 CET)

Conference call: April 26 (15:30 CET)

Annual General Meeting June 27 (Venlo)

Q2 results Media release: July 24 (22:00 CET)

Conference call: July 25 (15:30 CET)

Q3 results Media release: Oct 29 (22:00 CET)

Conference call: Oct 30 (15:30 CET)

Share informationNASDAQ: QGEN

Frankfurt: QIA

ISIN: NL0000240000

WKN: 901626

John GilardiVice President Corporate Communications and IRTel: +49 2103 29 11711

or +1 240 686 2222Mobile:

+49 1520 18 11711

E-mail: [email protected]

Albert FleuryDirector Corporate Finance and Investor Relations Tel: +1 301 944 7028Mobile:

+1 202 412 3871E-mail: [email protected]

58

Documents

Peer Schatz, Chief Executive Officer First Quarter 2012Sample & Assay Technologies. 3. Agenda. QIAGEN review. 2011 results. 2012 outlook. Appendix